LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics

LogicBio Therapeutics, Inc. (LOGC)

Today's Latest Price: $7.00 USD

0.00 (0.00%)

Updated Sep 25 4:00pm

Add LOGC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

LOGC Stock Summary

  • LOGC's went public 1.94 years ago, making it older than just 3.68% of listed US stocks we're tracking.
  • LOGC's price/sales ratio is 83.33; that's higher than the P/S ratio of 96.98% of US stocks.
  • Revenue growth over the past 12 months for LogicBio Therapeutics Inc comes in at 94.52%, a number that bests 94.47% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to LOGC, based on their financial statements, market capitalization, and price volatility, are ARCT, EVGN, ETTX, SYBX, and CDTX.
  • Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.
LOGC Daily Price Range
LOGC 52-Week Price Range

LOGC Stock Price Chart Technical Analysis Charts

LOGC Price/Volume Stats

Current price $7.00 52-week high $11.60
Prev. close $7.00 52-week low $3.05
Day low $6.92 Volume 648,141
Day high $7.75 Avg. volume 78,053
50-day MA $7.47 Dividend yield N/A
200-day MA $7.31 Market Cap 165.49M

LogicBio Therapeutics, Inc. (LOGC) Company Bio

LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.

LOGC Latest News Stream

Event/Time News Detail
Loading, please wait...

LOGC Latest Social Stream

Loading social stream, please wait...

View Full LOGC Social Stream

Latest LOGC News From Around the Web

Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.

How Much Did LogicBio Therapeutics'(NASDAQ:LOGC) Shareholders Earn From Share Price Movements Over The Last Year?

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...

Yahoo | September 14, 2020

LogicBio Therapeutics (LOGC) Catches Eye: Stock Jumps 7.1%

LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Yahoo | July 20, 2020

LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders

LogicBio Therapeutics, Inc. (Nasdaq:  LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (2020 Annual Meeting) will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our stockholders and other meeting participants. Stockholders will have the same rights and opportunities to participate in the virtual meeting as they would have at an in-person meeting. To gain access to the meeting, stockholders must go to the meeting website at http://www.meetingcenter.io/273338066.

Yahoo | June 5, 2020

Hedge Funds Cutting Exposure To LogicBio Therapeutics, Inc. (LOGC)

In this article we will take a look at whether hedge funds think LogicBio Therapeutics, Inc. (NASDAQ:LOGC) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 4, 2020

LogicBio Therapeutics to Present at the Jefferies Virtual Healthcare Conference

LogicBio Therapeutics, Inc. (LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET. LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. Headquartered in Lexington, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

Yahoo | May 28, 2020

Read More 'LOGC' Stories Here

LOGC Price Returns

1-mo 6.54%
3-mo -13.37%
6-mo 41.70%
1-year -26.32%
3-year N/A
5-year N/A
YTD -2.78%
2019 -30.77%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7926 seconds.